Blood eosinophils could be useful as a biomarker in COPD exacerbations.
Int J Clin Pract. 2019 Oct 01;:e13423
Authors: Gonzalez-Barcala FJ, San-Jose ME, Nieto-Fontarigo JJ, Calvo-Alvarez U, Carreira JM, Garcia-Sanz MT, Muñoz X, Perez-Lopez-Corona MP, Gómez-Conde MJ, Casas-Fernández A, Valdes-Cuadrado L, Mateo-Mosquera L, Salgado FJ
INTRODUCTION: The aim of analysing the usefulness of the blood eosinophil count (BEC) as a prognostic marker in exacerbations of patients with COPD, evaluating its relationship with hospital mortality, the length of stay, and the early and late re-admissions.
MATERIALS AND METHODS: We have carried out a retrospective study including all patients that required hospital admission between 1 January 2008 and 31 December 2009, with a diagnosis on hospital discharge of COPD exacerbation. These patients were classified using 3 cut-off points of BEC: less than 200 vs ≥200 /µL, less than 300 vs ≥300/µL, and less than 400 vs ≥400/µL.
RESULTS: There were a total of 1626 hospital admissions during the study period with the diagnosis of exacerbation of COPD. In this study we have included 358 patients. The probability of any late re-admission increased with a BEC ≥300/microlitre (Odds Ratio: 1.684) and for those with a BEC ≥400/microlitre (Odds Ratio: 2.068). The BEC does not appear to be related to hospital mortality or the probability of early re-admission after an exacerbation of COPD CONCLUSIONS: In our study an elevated BEC is associated with a higher incidence of late hospital readmissions in COPD exacerbations.
PMID: 31573721 [PubMed - as supplied by publisher]